Samsara BioCapital

General contacts

Investor type

Founded

2025

AUM

$1 600 M

Location

Palo Alto, California, United States

Investment Ticket

$10-50 m

Investment Stage

Series A Seed Series B Late Stage (Series C+)

Region of investment

North America Europe

ESG Focus

Impact investor

Investor profile last updated: 16 August, 2026

Profile

Samsara BioCapital is a venture capital firm based in the United States that primarily invests in biotechnology companies. The firm focuses on creating transformative therapeutics for patients, emphasizing a deep specialization in the life sciences sector. Headquartered in Palo Alto, Samsara BioCapital was founded by Srinivas Akkaraju, a prominent figure with significant expertise in the field of biotechnology venture investing.

Samsara BioCapital invests in early to late-stage companies within the life sciences field, with a core emphasis on biotechnology. The firm seeks to back companies in North America, providing capital to fuel the development of groundbreaking therapeutics. While specific check sizes are not disclosed, their focus on therapeutics aligns them with major life sciences investment capabilities.

Portfolio highlights include investments in companies such as Acelyrin, Alamar Biosciences, Janux Therapeutics, and Pathalys Pharma. These companies are involved in pioneering work ranging from drug development to innovative biotechnology processes, marking Samsara BioCapital's commitment to reshaping the therapeutic landscape.

Industry

Life Sciences Transportation Medical Devices Healthcare Services Digital Biotechnology HealthTech Pharmaceuticals MedTech

Samsara BioCapital Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
Samsara BioCapital	Venture Capital (VC)	Biotechnology Digital Healthcare Services Pharmaceuticals MedTech Life Sciences	Pre-seed Seed Series A Series B Late Stage (Series C+)	North America	$5-10 m	$310 M	March 2017

Contacts

Name

Title

Social Networks

Srini Akkaraju Managing General Partner

Managing General Partner

s•••@•••

Marcos Milla Venture Partner

Venture Partner

m•••@•••

Upgrade to see contacts

qhnSHTlNxz8U41F2 qhnSHTlNxz8U41F2

qhnSHTlNxz8U41F2

[email protected]

qhnSHTlNxz8U41F2 qhnSHTlNxz8U41F2

qhnSHTlNxz8U41F2

[email protected]

qhnSHTlNxz8U41F2 qhnSHTlNxz8U41F2

qhnSHTlNxz8U41F2

[email protected]

Investment-team contacts for Samsara BioCapital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Samsara BioCapital

Is Samsara BioCapital a venture capital or private equity firm?

Samsara BioCapital is a venture capital firm. It backs companies at Series A, Seed, Series B and Late Stage (Series C+), writing tickets of $10-50 m.

Where is Samsara BioCapital located?

Samsara BioCapital is located in Palo Alto, California, United States.

When was Samsara BioCapital founded?

Samsara BioCapital was founded in 2025.

What sectors and industries does Samsara BioCapital invest in?

Samsara BioCapital invests in companies and startups in Life Sciences, Transportation, Medical Devices, Healthcare Services, Digital, Biotechnology, HealthTech, Pharmaceuticals, MedTech.

What is Samsara BioCapital geographical focus of investments?

Samsara BioCapital invests in companies and startups in North America, Europe.

At what stages of companies and startups does Samsara BioCapital typically invest in?

Samsara BioCapital invests in companies and startups at Series A, Seed, Series B, Late Stage (Series C+).

What is the usual amount of Samsara BioCapital investment?

Samsara BioCapital usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for Samsara BioCapital?

Samsara BioCapital has around $1 600m assets under management.

When was Samsara BioCapital last fund created?

Samsara BioCapital last fund was created/launched in 2017-03-22

Is Samsara BioCapital impact investor?

Yes, Samsara BioCapital is impact investor.

What are the contacts of Samsara BioCapital?

Samsara BioCapital can be reached through its website samsaracap.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Samsara BioCapital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access Samsara BioCapital data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Samsara BioCapital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the Samsara BioCapital profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.